# US 2008/0269285 A1 · Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269285 A1
- Document ID: US20080269285A1
- Status: Published application
- Kind: A1
- Application number: 11/993,880
- Filed: 2006-06-22
- Published: 2008-10-30
- Earliest claimed: 2005-06-23
- Assignees: Centre National De La Recherche Scientifique
- Inventors: Olivier Richard Martin; Philippe Compain; Charlotte Boucheron; Naoki Asano
- Web page: https://patentgrep.com/patent/US20080269285A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention concerns the use of a compound of general formula (I) wherein: R0 represents in particular a hydrogen atom or an alkyl group; R1 represents in particular a hydrogen atom or an alkyl group; R2, R3 and R4 represent in particular, independently of one another, a hydrogen atom, a hydroxyl group, an alkoxy group or an acyloxy group, for preparing a medicine for treating lysosomal diseases related to a dysfunction of at least one lysosomal glycosidase enzyme.

## Claims

### Claim 1

Method for the treatment of lysosomal diseases linked to a dysfunction of at least one lysosomal glycosidase enzyme comprising administering to a patient in need thereof of a compound of the following general formula (I):
in which:
R0 represents:
a hydrogen atom, or
a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 12 carbon atoms, said alkyl group being optionally substituted by a phenyl group, if appropriate substituted by an alkoxy group comprising 1 to 15 carbon atoms, or
an oxaalkyl group comprising 3 to 12 members,
R1 represents:
a hydrogen atom, or
a linear or branched, saturated or unsaturated alkyl group, comprising 4 to 16 carbon atoms, said alkyl group being optionally substituted by or carrying a substituent chosen from the following groups: hydroxyl, alkoxy comprising 1 to 12 carbon atoms and phenyl, or
an n-oxaalkyl group comprising 4 to 12 members, n representing an integer greater than or equal to 3,
R2, R3 and R4 represent, independently of one another:
a hydrogen atom, or
a hydroxyl group, or
an alkoxy group of formula OR5, R5 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms or a benzyl group, or
an acyloxy group of formula O—CO—R6, R6 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms,
at least one of the groups R1, R2, R3 and R4 representing a linear or branched, saturated or unsaturated alkyl group, comprising 4 to 16 carbon atoms as defined above, or representing a group comprising a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms as defined above,
said compound of formula (I) being in the form of a pure stereoisomer or in the form of a mixture of enantiomers and/or of diastereoisomers, including racemic mixture as well as their addition salts with pharmacologically acceptable acids,
providing that:
in formula (I), when R0 represents a hydrogen atom or an alkyl group comprising 1 to 3 carbon atoms and R1 represents a hydrogen atom, at least one of the groups R2, R3 and R4 represents an alkoxy group, OR5, or acyloxy group, OCOR6, as defined above, in which R5 or R6 represents an alkyl group comprising at least 3 carbon atoms, and
in formula (I), at least two of the groups R2, R3 and R4 do not represent a hydrogen atom.

### Claim 2 (depends on 1)

Method according to claim 1 wherein R0 represents a linear or branched, saturated or unsaturated alkyl group comprising 4 to 12 carbon atoms.

### Claim 3 (depends on 2)

Method according to claim 2 wherein R0 represents a linear or branched, saturated or unsaturated alkyl group comprising 6 to 12 carbon atoms.

### Claim 4 (depends on 1)

Method according to claim 1 wherein R5 represents a linear or branched, saturated or unsaturated alkyl group comprising 4 to 12 carbon atoms.

### Claim 5 (depends on 1)

Method according to claim 1, wherein the lysosomal disease is the Gaucher's disease.

### Claim 6 (depends on 1)

Method according to claim 1, wherein the lysosomal disease is the Krabbe's disease.

### Claim 7 (depends on 1)

Method according to claim 1, wherein the lysosomal disease is the Fabry's disease.

### Claim 8 (depends on 1)

Method according to claim 1, wherein R0 represents a hydrogen atom.

### Claim 9 (depends on 8)

Method according to claim 8, wherein R1 represents an alkyl group comprising 4 to 16 carbon atoms.

### Claim 10 (depends on 9)

Method according to claim 9 wherein R1 represents an alkyl group comprising 9 carbon atoms.

### Claim 11 (depends on 8)

Method according to claim 8 wherein R2, R3 and R4 represent an OH group.

### Claim 12 (depends on 9)

Method according to claim 9 wherein R2, R3 and R4 represent an OH group.

### Claim 13 (depends on 10)

Method according to claim 10 wherein R2, R3 and R4 represent an OH group.

### Claim 14 (depends on 1)

Method according to claim 1, wherein R0 represents an alkyl group comprising 6 to 12 carbon atoms.

### Claim 15 (depends on 14)

Method according to claim 14, wherein R0 represents an alkyl group comprising 9 carbon atoms.

### Claim 16 (depends on 14)

Method according to claim 14 wherein R1 represents a hydrogen atom.

### Claim 17 (depends on 14)

Method according to claim 14 wherein R2 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 3 to 15 carbon atoms.

### Claim 18 (depends on 17)

Method according to claim 17 wherein R2 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 4 to 12 carbon atoms.

### Claim 19 (depends on 16)

Method according to claim 16 wherein R2 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 3 to 15 carbon atoms.

### Claim 20 (depends on 19)

Method according to claim 19 wherein R2 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 4 to 12 carbon atoms.

### Claim 21 (depends on 14)

Method according to claim 14, wherein R3 and R4 represent OH groups.

### Claim 22 (depends on 16)

Method according to claim 16, wherein R3 and R4 represent OH groups.

### Claim 23 (depends on 17)

Method according to claim 17, wherein R3 and R4 represent OH groups.

### Claim 24 (depends on 14)

Method according to claim 14 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 3 to 15 carbon atoms.

### Claim 25 (depends on 24)

Method according to claim 24 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 4 to 12 carbon atoms.

### Claim 26 (depends on 16)

Method according to claim 16 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 3 to 15 carbon atoms.

### Claim 27 (depends on 26)

Method according to claim 26 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 4 to 12 carbon atoms.

### Claim 28 (depends on 17)

Method according to claim 17 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 3 to 15 carbon atoms.

### Claim 29 (depends on 28)

Method according to claim 28 wherein R3 represents an OH group and R4 represents an alkoxy group of formula OR5, R5 representing an alkyl group comprising 4 to 12 carbon atoms.

### Claim 30 (depends on 1)

Method according to claim 1 wherein the administered compound has the following general formula (II):
R0, R1, R2, R3 and R4 being as previously defined.

### Claim 31 (depends on 30)

Method according to claim 30, wherein the administered compound has the following formula (III):
in which R1 represents a linear or branched, saturated or unsaturated alkyl group, comprising 4 to 16 carbon atoms, said alkyl group being optionally substituted by or carrying a substituent chosen from the following groups: hydroxyl, alkoxy comprising 1 to 12 carbon atoms and phenyl

### Claim 32 (depends on 31)

Method according to claim 31 wherein R1 is a nonyl group.

### Claim 33 (depends on 30)

Method according to claim 30, wherein the compound has the following formula (IV):
in which:
p represents an integer varying from 0 to 11,
R0 represents a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 12 carbon atoms, said alkyl group being optionally substituted by a phenyl group, if appropriate substituted by an alkoxy group comprising 1 to 15 carbon atoms.

### Claim 34 (depends on 30)

Method according to claim 30, wherein the compound has the following formula (V):
in which:
p represents an integer varying from 0 to 11,
R0 represents a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 12 carbon atoms, said alkyl group being optionally substituted by a phenyl group, if appropriate substituted by an alkoxy group comprising 1 to 15 carbon atoms.

### Claim 35

Compound of the following general formula (I):
in which:
R0 represents:
a hydrogen atom, or
a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 12 carbon atoms said alkyl group being optionally substituted by a phenyl group, if appropriate substituted by an alkoxy group comprising 1 to 15 carbon atoms, or
an oxaalkyl group comprising 3 to 12 members,
R1 represents:
a hydrogen atom, or
a linear or branched, saturated or unsaturated alkyl group, comprising 4 to 16 carbon atoms, said alkyl group being optionally substituted by or carrying a substituent chosen from the following groups: hydroxyl, alkoxy comprising 1 to 12 carbon atoms and phenyl, or
an n-oxaalkyl group comprising 4 to 12 members, n representing an integer greater than or equal to 3,
R2, R3 and R4 represent, independently of one another:
a hydrogen atom, or
a hydroxyl group, or
an alkoxy group of formula OR5, R5 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms or a benzyl group, or
an acyloxy group of formula O—CO—R6, R6 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms,
at least one of the groups R1, R2, R3 and R4 representing a linear or branched, saturated or unsaturated alkyl group, comprising 4 to 16 carbon atoms as defined above, or representing a group comprising a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms as defined above,
said compound of formula (I) being in the form of a pure stereoisomer or in the form of a mixture of enantiomers and/or of diastereoisomers, including a racemic mixture as well as their addition salts with pharmacologically acceptable acids,
providing that:
in formula (I), when R0 represents a hydrogen atom or an alkyl group comprising 1 to 3 carbon atoms and R1 represents a hydrogen atom, at least one of the groups R2, R3 and R4 represents an alkoxy group OR5 or acyloxy OCOR6 as defined above, in which R5 or R6 represents an alkyl group comprising at least 3 carbon atoms, and
in formula (I), at least two of the groups R2, R3 and R4 do not represent a hydrogen atom.

### Claim 36 (depends on 35)

Method according to claim 35 wherein R0 represents a linear or branched, saturated or unsaturated alkyl group comprising 4 to 12 carbon atoms.

### Claim 37 (depends on 35)

Method according to claim 35 wherein R0 represents a linear or branched, saturated or unsaturated alkyl group comprising 6 to 12 carbon atoms.

### Claim 38 (depends on 35)

Method according to claim 35 wherein R5 represents a linear or branched, saturated or unsaturated alkyl group comprising 4 to 12 carbon atom.

### Claim 39 (depends on 35)

Compound according to claim 35, corresponding to the following formula (II):
R0, R1, R2, R3 and R4 being as previously defined.

### Claim 40 (depends on 35)

Compound according to claim 35, corresponding to the following formula (III):
in which R1 represents an alkyl group as previously defined.

### Claim 41 (depends on 35)

Compound according to claim 35, corresponding to the following formula (IV):
in which:
p represents an integer varying from 0 to 11,
R0 represents an alkyl group as previously defined.

### Claim 42 (depends on 35)

Compound according to claim 35, corresponding to the following formula (V):
in which:
p represents an integer varying from 0 to 11,
R0 represents an alkyl group as previously defined.

### Claim 43 (depends on 35)

Composition pharmaceutical comprising a compound according to claim 35, in combination with a pharmaceutically acceptable vehicle.

### Claim 44 (depends on 17, 35)

Process for the preparation of a compound of formula (I) according to claim 35, in which R1 represents an alkyl group or an n-oxaalkyl group, comprising the following stages:
a) the addition of an organometallic compound of formula R1-M, in which R1 represents an alkyl group or an n-oxaalkyl group as previously defined, M represents a metal or a group MgX in which X represents a halogen atom, on an imine of the following formula (1):
in which:
GP0 represents a protective group selected from the group comprising the allyl, benzyl, p-methoxybenzyl and 2-naphthalenemethyl groups, and
GP3 represents a protective group selected from the group comprising the allyl, benzyl and 2-naphthalenemethyl groups,
in order to obtain a compound of the following formula (2):
in which GP0, GP3 and R1 are as defined above,
b) the hydrolysis in acid medium of the compound of formula (2) as defined above, followed by an intramolecular reductive amination reaction, in order to obtain a substituted piperidine of the following formula (3):
GP0, GP3 and R1 being as defined above,
the compound of formula (3) being, if appropriate, deprotected in order to obtain a compound of formula (III),
said compound of formula (III) thus obtained being then optionally subjected to a stage of alkylation of the free amine function, said step being selected from the group comprising alkylation with an alkyl halide R0X and reductive amination with an aldehyde originating from the oxidation of an alcohol of formula R0OH, R0 representing an alkyl group or an oxaalkyl group as previously defined, in order to obtain a compound of formula (II) in which R2, R3 and R4 represent an OH group,
c) the protection of the free OH functions of the abovementioned compound (3), in order to obtain a substituted piperidine of the following formula (4):
in which:
GP2 represents a protective group selected from the group comprising the acetyl, benzoyl and pivaloyl groups,
GP4 represents a protective group selected from the group comprising the trialkylsilyl groups, and
GP0, GP3 and R1 are as defined above,
d) the chemoselective deprotection of one of the groups GP2, GP3 or GP4, of the compounds of the abovementioned formula (4), in order to obtain respectively a compound of the following formula (5):
in which:
A2 represents a hydrogen atom or a protective group GP2,
A3 represents a hydrogen atom or a protective group GP3,
A4 represents a hydrogen atom or a protective group GP4,
and only one of the groups A2, A3 and A4 represents H,
GP0, GP2, GP3, GP4, and R1 being as defined above,
e) the reaction of the free hydroxyl function of the abovementioned compounds of formula (5),
either within the framework of the implementation of an alkylation process, selected from the group comprising alkylation with an alkyl halide of formula R5—X, X representing a halogen atom, and R5 representing an alkyl group comprising 3 to 15 carbon atoms, in order to obtain a compound of the following formula (6):
in which:
B2 represents a group R5 or a protective group GP2,
B3 represents a group R5 or a protective group GP3,
B4 represents a group R5 or a protective group GP4,
and only one of the groups B2, B3 and B4 represents R5,
GP0, GP2, GP3, GP4, and R1 being as defined above,
either within the framework of the implementation of an acylation process, for example with an acid chloride of formula R6COCl, R6 being as previously defined, in order to obtain a compound of the following formula (7):
in which:
C2 represents a group COR6 or a protective group GP2,
C3 represents a group COR6 or a protective group GP3,
C4 represents a group COR6 or a protective group GP4,
and only one of the groups C2, C3 and C4 represents COR6,
GP0, GP2, GP3, GP4, and R1 being as defined above,
or within the framework of the implementation of a deoxidation process, for example by reaction with Im2CS then Bu3SnH, in order to obtain one of the compounds of the following formula (8):
in which:
D2 represents a hydrogen atom or a group OGP2,
D3 represents a hydrogen atom or a group OGP3,
D4 represents a hydrogen atom or a group OGP4,
and only one of the groups D2, D3 and D4 represents H,
GP0, GP2, GP3, GP4, and R1 being as defined above,
or within the framework of the implementation of a configuration inversion process, for example by the implementation of the Swern reaction, followed by reduction with a boron hydride, in order to obtain one of the compounds of the following formulae (9-1), (9-2) or (9-3):
GP0, GP2, GP3, GP4, and R1 being as defined above,
the abovementioned compounds of formulae (6), (7), (8), (9-1), (9-2) and (9-3) being able to be deprotected in order to obtain respectively the compounds of the following formulae (I-6), (I-7), (I-8), (I-9-1), (I-9-2) and (I-9-3), corresponding to compounds of formula (I) as previously defined:
in which:
B′2 represents a group R5 or a hydrogen atom,
B′3 represents a group R5 or a hydrogen atom,
B′4 represents a group R5 or a hydrogen atom,
and only one of the groups B′2, B′3 and B′4 represents R5,
C′2 represents a group COR6 or a hydrogen atom,
C′3 represents a group COR6 or a hydrogen atom,
C′4 represents a group COR6 or a hydrogen atom,
and only one of the groups C′2, C′3 and C′4 represents COR6,
D′2 represents a hydrogen atom or an OH group,
D′3 represents a hydrogen atom or an OH group,
D′4 represents a hydrogen atom or an OH group,
and only one of the groups D′2, D′3 and D′4 represents H,
the compounds thus obtained of formulae (I-6), (I-7), (I-8), (I-9-1), (I-9-2) and (I-9-3) being able to then be optionally subjected to a stage of alkylation of the free amine function, for example by alkylation with an alkyl halide R0X or by reductive amination with an aldehyde originating from the oxidation of an alcohol of formula R0OH, R0 representing an alkyl group or an oxaalkyl group as defined in claim 17, in order to obtain the compounds of the following formulae (I-6-a), (I-7-a), (I-8-a), (I-9-1-a), (I-9-2-a) and (I-9-3-a), corresponding to compounds of formula (I) as previously defined:
B′2, B′3, B′4, C′2, C′3, C′4, D′2, D′3, D′4, R0and R1 being as defined above,
f) and, optionally, the regioselective deprotection of one of the remaining protective groups GP2, GP3 or GP4, of the abovementioned compounds of formula (6), (7), (8), (9-1), (9-2) or (9-3) in order to obtain a deprotected free hydroxyl function, and the reaction of this free hydroxyl function, as described previously in Stage e), either within the framework of the implementation of an alkylation process, or within the framework of the implementation of an acylation process, or within the framework of the implementation of a deoxidation process, or within the framework of the implementation of a configuration inversion process, and an optional stage of deprotection in order to obtain compounds of formula (I) as defined above, optionally followed by a stage of alkylation of the free amine function, for example by alkylation with an alkyl halide R0X or by reductive amination with an aldehyde originating from the oxidation of an alcohol of formula R0OH, R0 representing an alkyl group or an oxaalkyl group as previously defined, in order to obtain compounds of formula (I) in which R0 is different from a hydrogen atom,
Stage f) being able to be optionally repeated if the compound obtained of formula (I) also contains a free hydroxyl function.

### Claim 45 (depends on 17)

Process for the preparation of a compound of formula (I) according to claim 17, in which R1 represents a hydrogen atom, comprising the following stages:
a) the reaction of a compound of the following formula (10):
in which GP3 represents a protective group in particular chosen from the allyl, benzyl and 2-naphthalenemethyl groups,
with a reagent containing an activating group Y, in order to obtain the compound of the following formula (11):
Y—O representing a leaving group, in which Y is an activating group in particular chosen from the mesyl, p-toluenesulphonyl and trifluoromethanesulphonyl groups,
b) the substitution of the compound of the abovementioned formula (11) by a primary amine R0NH2, R0 representing an alkyl or oxaalkyl group as previously defined, in order to obtain a compound of the following formula (12):
GP3 being as defined above,
c) the hydrolysis in acid medium of the compound of formula (12) as defined above, followed by an intramolecular reductive amination reaction, in order to obtain a substituted piperidine of the following formula (13):
GP3 and R0 being as defined above,
d) the reaction of the compound of the abovementioned formula (13) with a compound of formula R5X, R5 being as previously defined and X representing a halogen atom, or with an acid chloride R6COCl, R6 being as previously defined, in order to obtain one of the following compounds (14-1) or (14-2):
R7 representing a group COR6 or a group R5 as defined above,
GP3 and R0 being as defined above,
the compounds of formulae (14-1) and (14-2) being in particular separated by silica gel chromatography,
the compound of formula (14-2) being, if appropriate, deprotected in order to obtain a compound of the following formula (I):
R7 and R0 being as defined above,
e) the regioselective deprotection of the group OGP3 of the compound of formula (14-1) in order to obtain the compound of the following formula (14-3) containing a free hydroxyl function and corresponding to a compound of formula (I):
R7 and R0 being as defined above,
f) the reaction of the free hydroxyl function of the abovementioned compounds of formula (14-2) and (14-3),
either within the framework of the implementation of an alkylation process, for example with an alkyl halide of formula R5—X, X representing a halogen atom, and R5 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms, or a benzyl group, or
an acyloxy group of formula O—CO—R6, R6 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms,
in order to obtain respectively a compound of the following formula (15-2) or (15-3):
GP3, R5, R7 and R0 being as defined above,
the compound of formula (15-2) then being deprotected in order to obtain a compound of the following formula (I):
R5, R7 and R0 being as defined above,
or within the framework of the implementation of an acylation process, for example with an acid chloride of formula R6COCl, R6 representing a linear or branched, saturated or unsaturated alkyl group, comprising 1 to 15 carbon atoms,
in order to obtain respectively a compound of the following formula (16-2) or (16-3):
GP3, R6, R7 and R0 being as defined above,
the compound of formula (16-2) then being deprotected in order to obtain a compound of the following formula (I):
R6, R7 and R0 being as defined above,
or within the framework of the implementation of a deoxidation process, for example by reaction with Im2CS then Bu3SnH, in order to obtain respectively a compound of the following formula (17-2) or (17-3):
GP3, R7 and R0 being as defined above,
the compound of formula (17-2) then being deprotected in order to obtain a compound of the following formula (I):
R7 and R0 being as defined above,
or within the framework of the implementation of a configuration inversion process, for example by the implementation of the Swern reaction, followed by reduction with a boron hydride, in order to obtain respectively a compound of the following formula (18-2) or (18-3):
GP3, R7 and R0 being as defined above,
the compound of formula (18-2) then being deprotected in order to obtain a compound of the following formula (I):
R7 and R0 being as defined above.
